Again, all checks to assess cellular immunity among individuals with a previous illness were reactive. The Arf6 level of cellular immunity was higher for participants who received two doses of mRNA-based vaccines, and particularly the schedule ChAdOx1/ChAdOx1 among COVID-19 nave individuals showed the lowest level of IFN- production after stimulation. of antibodies among COVID-19 nave participants was 98, 111, 60 and 36 days, for mRNA-1273, BNT162b2, ChAdOx1/ChAdOx1 and ChAdOx1/BNT162b2, respectively. Cellular immunity was maintained in 96%, 98%, 88% and 92% of uninfected individuals who received mRNA-1273, BNT162b2, ChAdOx1/ChAdOx1 and ChAdOx1/BNT162b2 after 6/9 weeks. Individuals with specific T cells showed robust long lasting protection, especially when m-RNA centered vaccines are inoculated. These data may influence the validity of the vaccination passport and the need for booster vaccinations. Subject terms:Vaccines, Viral illness, Viral illness == Intro == Coronavirus disease 2019 (COVID-19) offers affected more than 530 million people and 6.3 million deaths possess been recorded globally1since the declaration of pandemics by the World Health Organization RGDS Peptide in March 2020. However, recent estimations suggest that 3.4 billion individuals or 44% of the global human population, had been infected one or more instances by SARS-CoV-2 disease before 20222and that 18.2 million people died worldwide following SARS-CoV-2 illness over that period3. The quick development of vaccines able to prevent fresh instances and decrease severity and lethality was imperative, leading to five COVID-19 vaccines authorized in Europe based on mRNA, adenovirus or recombinant proteins: mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNtech), ChAdOx1 nCoV-19 (AZD1222; Oxford-AstraZeneca), Ad26.COV2.S (Janssen) and NVX-CoV2373 (Novavax)4. Soon after the authorization, vaccination campaigns across Europe began. So far, over 11.4 billion vaccine doses possess been given worldwide. These vaccines shown impressive effectiveness and safety against slight and severe COVID-19 disease in medical tests57. However, vaccine effectiveness or performance against illness and symptomatic disease decreased approximately 2030 percentage points by 6 months, although safety against severe disease remained greater than 70% over time8,9. This reduction may be due to RGDS Peptide a loss of immunity, the blood circulation of fresh VOCs with the ability to evade the immune response, or a combination of both. In addition, some studies have shown that people who have undergone COVID-19 disease do not need a second dose if a first dose of mRNA vaccine has been administered10. Specific T cells are detectable as early as 714 days post-vaccination or 35 days after onset of symptoms during natural illness, whereas binding and neutralizing antibodies are present at low titers at this early phase, and levels maximum approximately at 1421 days post-vaccination. Further data within the longevity of humoral and T-cell response is required to establish improving schedules and measure the vaccine`s ability to identify and protect against variants11. Humoral and cellular immunogenicity of different homologous and heterologous mixtures of mRNA and adenovirus-based vaccines have not been simultaneously compared during a long follow-up to assess the decline of each particular vaccine brand12. These data may be very useful when there are issues around vaccine supply or vaccination passport validity, and further assessments are needed within the duration of the immune response, important for updating COVID-19 vaccine plans. We conducted a study in healthcare workers to understand the kinetics RGDS Peptide of humoral and cellular immunity during 69 weeks which could clarify waning of vaccine-induced safety after vaccination with 5 different vaccine schedules. == Results == Seven hundred and nine subjects were enrolled and subgrouped depending on the vaccine received (Table1). The mean age of individuals was 44 11 years old and 85.9% were women. == Table 1. == Description of participants according to the type RGDS Peptide of vaccine inoculated. 1 dose 21-days follow-up 2 dosesa 21-days follow-up 2 dosesa 3-weeks follow-up 2 dosesa 6-weeks follow-up 2 dosesa 9-weeks follow-up 1 dose 21-days follow-up 2 doses 21-days follow-up 2 doses 3-weeks follow-up 2 doses 6-weeks follow-up 2 doses 9-weeks follow-up a2 doses of mRNA-1273, BNT162b2, ChAdOx1/ChAdOx1 or ChAdOx1/BNT162b2 schedules or one single dose of ChAdOx1 vaccine. == Humoral immunity == Significant variations were found in all vaccines subgroups in the production of anti-RBD antibodies after receiving one or two doses in those individuals who had not undergone earlier COVID-19 infection. However, no variations were found between individuals with a history of COVID-19 within the mRNA-1273 and BNT162b2 organizations, after receiving the second dose (Fig.1). == Number 1. == Anti-S-RBD (U/mL) levels after administration of one or two doses (21 days follow-up). mRNA-1273 (green), BNT162b2 (reddish) or ChAdOx1 (black/blue) vaccines among individuals with previous COVID-19 illness (Pos) or not (Neg) (ChAdOx1/ChAdOx1 (AZ): black; ChAdOx1/BNT162b2 (Pf): blue) (**p < 0.01; ***p < 0.001). The inoculation of.